Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment.

Byooviz (ranibizumab-nuna) - Samsung, AffaMed Therap, Biogen

Cimerli (ranibizumab-eqrn) - Amneal, Formycon, Coherus Biosci, Teva

RanizuRel (ranibizumab biosimilar) - Reliance Life Sci

Lucentis (ranibizumab) - Roche, Novartis

http://www.ncbi.nlm.nih.gov/pubmed/37493655

Amin Hatamnejad; Charles Wykoff; Netan Choudhry; Rohan Dadak; Samantha Orr

Jul 26, 2023